<?xml version="1.0" encoding="UTF-8"?>
<org.eclipse.epf.uma:ContentDescription xmi:version="2.0" xmlns:xmi="http://www.omg.org/XMI" xmlns:org.eclipse.epf.uma="http://www.eclipse.org/epf/uma/1.0.6/uma.ecore" xmlns:epf="http://www.eclipse.org/epf" epf:version="1.5.1" xmlns:rmc="http://www.ibm.com/rmc" rmc:version="7.5.1" xmi:id="-uos5OaOActx1q-17UGALOg" name="new_concept,_rdGFIMB9EeGh1OUl278fdA" guid="-uos5OaOActx1q-17UGALOg" changeDate="2012-06-27T10:32:55.016-0700">
  <mainDescription>&lt;h4>&#xD;
    Overview&#xD;
&lt;/h4>&#xD;
&lt;p>&#xD;
    An important aspect of bringing Commercial-Off-The-Shelf (COTS) software into a US Food and Drug Administration (FDA)&#xD;
    regulated environment is the execution of Intended Use, or Fit for Purpose, Validation (IUV).&#xD;
&lt;/p>&#xD;
&lt;p>&#xD;
    The information in this guide is not to be considered official FDA or EMEA regulation or guidance. Rather, it is an&#xD;
    aggregation of consolidated best practices gathered from field experience. It is incumbent upon to the individual&#xD;
    development team(s) to take this information and modify it according to their own specific regulatory needs.&#xD;
&lt;/p>&#xD;
&lt;h4>&#xD;
    What is IUV?&#xD;
&lt;/h4>&#xD;
&lt;p>&#xD;
    A software tool&amp;nbsp;is considered ‘regulated non-medical device’ or ‘quality effect’ software. These are terms given&#xD;
    to COTS software that is used by stakeholders, engineers, testers and management to assist them in the design and&#xD;
    development of medical devices. It is NOT software that goes into the medical device. IUV occurs only against&#xD;
    functionality that will be used as defined by the client’s process. IUV is not exhaustive testing of a COTS product nor&#xD;
    is it a ‘bug bash’.&#xD;
&lt;/p>&#xD;
&lt;h4>&#xD;
    Why do IUV?&#xD;
&lt;/h4>&#xD;
&lt;p>&#xD;
    The FDA is primarily looking for two things:&#xD;
&lt;/p>&#xD;
&lt;ol>&#xD;
    &lt;li>&#xD;
        Evidence of a Quality Management System (QMS) that defines the IUV process.&#xD;
    &lt;/li>&#xD;
    &lt;li>&#xD;
        Evidence that the process is followed in the form of auditable documents and reports.&#xD;
    &lt;/li>&#xD;
&lt;/ol>&#xD;
&lt;p>&#xD;
    Listed are some of the commonly applicable regulations:&#xD;
&lt;/p>&#xD;
&lt;ul>&#xD;
    &lt;li>&#xD;
        FDA Guidance 21 CFR part 820.30 - Design Controls&#xD;
    &lt;/li>&#xD;
    &lt;li>&#xD;
        FDA Guidance 21 CFR part 820.70i - &quot;Production and Process Controls: Automated Processes&quot;&#xD;
    &lt;/li>&#xD;
    &lt;li>&#xD;
        ISO 13485 &quot;Medical Devices - Quality Management Systems: Requirements for regulatory purposes&quot;&#xD;
    &lt;/li>&#xD;
    &lt;li>&#xD;
        ISO 9001, Quality Management Systems - Requirements&#xD;
    &lt;/li>&#xD;
    &lt;li>&#xD;
        ISO 14971 &quot;Medical Devices - Application of Risk Management to Medical Devices&quot;&#xD;
    &lt;/li>&#xD;
    &lt;li>&#xD;
        Potentially 21 CFR part 11 - Electronic Records Management, if DOORS will be used as the official record for parts&#xD;
        of the Design History File (DHF).&#xD;
    &lt;/li>&#xD;
&lt;/ul>&#xD;
&lt;h4>&#xD;
    When to do IUV?&#xD;
&lt;/h4>&#xD;
&lt;p>&#xD;
    An IUV is typically performed at a point in time when any of the following conditions occur:&#xD;
&lt;/p>&#xD;
&lt;ul>&#xD;
    &lt;li>&#xD;
        When a new tool is first introduced into an organization’s development environment.&#xD;
    &lt;/li>&#xD;
    &lt;li>&#xD;
        When a new version of&amp;nbsp;a tool&amp;nbsp;is adopted by an existing user. A full version increase, such as 8.x -&amp;gt;&#xD;
        9.x may mandate a full (re)validation. A point release such as 9.1 -&amp;gt; 9.4 may only necessitate an incremental&#xD;
        validation.&#xD;
    &lt;/li>&#xD;
    &lt;li>&#xD;
        The user’s Quality System Process changes to include functionality not previously IUVd. For example, past processes&#xD;
        allowed only for printing documents for ‘wet’ signature approval, while new processes allow for electronic baseline&#xD;
        and e-signature.&#xD;
    &lt;/li>&#xD;
&lt;/ul></mainDescription>
</org.eclipse.epf.uma:ContentDescription>
